Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

FGFR2
Biological Pathway Review

Advertisement

Advertisement

Expression in Cancer

Breast Cancer

Approximately 2% to 4% of breast cancer have FGFR2 sequence variations.3 Patients with FGFR2 amplification breast cancer tend to respond well to FGF inhibition treatment.3

Gastric Cancer

Around 10% of patients with gastric cancer experience upregulation of FGFR2.3 This upregulation is associated with diffuse cancer and with a worse prognosis.3

Hepatocellular Carcinoma

FGFR2 overexpression is associated with a high recurrence rate of HCC following hepatic resection.4

Lung Cancer

Sequence variations to FGFR2 occur in 5% of squamous NSCLC.5

FGFR2 Biological Pathways Reviews

FGFR2

Fibroblast growth factor receptor 2 (FGFR2), a tyrosine kinase, induces downstream signaling. When FGFR2 is dysregulated, it can cause tumor progression and cancer.1 FGFR2 alterations have been observed in 1.77% of all human cancers.2 FGF2 has potent angiogenic activity, inhibition of this tyrosine kinase can reduce tumor angiogenesis.3

Understanding the Role of FGFR2

Videos

Vivek Subbiah, MD, Sarah Cannon Research Institute
Videos
Management of Adverse Events Associated With FGFR Inhibitors
12/12/2023
Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.
Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.
Vivek Subbiah, MD, discusses the...
12/12/2023
Oncology
Expert Roundtable
Videos
Selecting Optimal First-Line Therapies for Patients With Acute Myeloid Leukemia
11/07/2024
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert...
11/07/2024
Oncology
Expert Roundtable
Videos
Diagnosis and Risk Stratification of Acute Myeloid Leukemia
11/07/2024
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert...
11/07/2024
Oncology
Videos
Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer
11/05/2024
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of Alabama at Birmingham, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.
Aakash Desai, MD, University of...
11/05/2024
Oncology
John Leonard, MD
Videos
Highlights in Novel Therapies for Lymphomas From the LL&M Congress
11/05/2024
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Hodgkin Lymphoma From the LL&M Congress
11/05/2024
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Diffuse Large B-Cell Lymphoma From the LL&M Congress
11/05/2024
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Mantle Cell Lymphoma From the LL&M Congress
11/05/2024
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
Jonathan Riess, MD
Conference Coverage
IO102-IO103 Plus Pembrolizumab Demonstrates Potential for Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
10/31/2024
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses...
10/31/2024
Oncology
Elisabeth Livingstone, MD
Conference Coverage
Early Switch From Targeted to Immunotherapy for Patients With Advanced BRAF V600-Positive Melanoma
10/31/2024
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD,...
10/31/2024
Oncology
Andrea Botticelli, MD
Conference Coverage
Using Comprehensive Genome Profiling to Guide Treatment for Patients With Metastatic Solid Tumors
10/31/2024
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD,...
10/31/2024
Oncology

Podcasts

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
Advances in Genetic Testing for Patients With Gastrointestinal Cancers
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab Yields Encouraging Response Rates in Metastatic Urothelial Cancer
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
Maintenance Therapy With Cabozantinib Shows No Significant Benefit vs Placebo for Metastatic Urothelial Carcinoma
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Resources

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Interactive Features

Quiz
Osimertinib For Progressive EGFR-Mutated T790M-Negative NSCLC
04/25/2023
How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?
How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?
How did patients with...
04/25/2023
Oncology
Test Your Knowledge
L858R Mutation by Stage in EGFR-Mutated Lung Cancer
04/13/2023
Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?
Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?
Is there a difference in L858R...
04/13/2023
Oncology
Quiz
Are PD-L1 Scores Predictive of TP53 Mutation Rates?
02/13/2023
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.
A study investigated a potential...
02/13/2023
Oncology
Quiz
Quiz: Targeted Therapies for EGFR-Mutant Lung Cancer
12/02/2022
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?
What study recently provided an...
12/02/2022
Oncology
Test Your Knowledge
Quiz: Combination Therapies as Treatment Options for EGFR-Mutated Lung Cancer
11/30/2022
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?
Which combination therapies are...
11/30/2022
Oncology
Quiz
Quiz: Which somatic missense non-synonymous single nucleotide polymorphisms were recently determined to be putative novel rare genetic markers for NSCLC?
10/12/2022
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?
After analyzing a selected pool...
10/12/2022
Oncology
Quiz
Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC
07/25/2022
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?
In the single-arm CHRYSALIS...
07/25/2022
Oncology
Medical
Test Your Knowledge
Quiz: How Does Tisagenlecleucel Affect Activity in ALL?
03/07/2022
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel does not affect activity in young patients with R/R B-cell ALL and adult patients with R/R DLBCL.
True or false: Tisagenlecleucel...
03/07/2022
Oncology
Test Your Knowledge
Quiz: Is This Selective FGFR Inhibitor Safe to Treat Hematologic Malignancies?
02/25/2022
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101...
02/25/2022
Oncology
Test Your Knowledge
Quiz: Does This Pan-FGFR TKI Show Long-Term Efficacy?
02/25/2022
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a...
02/25/2022
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement